Evidence map›Paper›PMID 39635591›Full record

ArticleFrontiers in medicine2024

The efficacy and safety of remimazolam in painless colonoscopy: a prospective, randomized clinical trial.

Haobing Shi, Jinyuan Zhang, Zhiqiang Hu, Qianhao Hou, Qianhua Hu, Zhiguang Dai, Wenjuan Zhou, Dingwu Qi, Yuling Li, Qing Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Sedation in endoscopy: Current practices and future innovations.World journal of gastrointestinal endoscopy · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Haobing ShiDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jinyuan ZhangDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhiqiang HuDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Qianhao HouDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Qianhua HuDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Zhiguang DaiDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Wenjuan ZhouDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Dingwu QiDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Yuling LiDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Qing WangDepartment of Anesthesiology, Ji'an Hospital, Shanghai East Hospital, Medical School, Tongji University, Shanghai, China.
Xiangrui WangDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Lijun LiaoDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shuwen QianDepartment of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Remimazolam is a new type of ultra-short-effect intravenous anesthetic, that may provide adequate sedation for endoscopy while causing less cardiovascular or respiratory disturbance than propofol. The aim of this clinical study was to compare the efficacy and safety of two different doses of remimazolam with propofol for sedation during colonoscopy. Patients and methods: 225 subjects, aged 18 to 80 years, with American Society of Anesthesiology physical status I-III, were scheduled to undergo colonoscopy. All the subjects were randomly assigned to three groups, Low-Rem group (low dose remimazolam, 0.15 mg/kg, iv, Results: The success rate of colonoscopy procedure was 100% in both High-Rem and Propofol groups, but it was 89% in Low-Rem group ( Conclusion: Remimazolam can be used safely and effectively for colonoscopy. 0.2 mg/kg remimazolam and propofol have the same sedation success rate and more stable hemodynamics and fewer side effects than propofol. Clinical trial registration: ChiCTR2100054053.

Indexed as

anesthesiacolonoscopypropofolremimazolamsedation

Identifiers

PMID39635591
PMCPMC11614597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.